# 中外製薬（4519） エフ・ホフマン・ラ・ロシュの2026年中間決算発表について

Source: Komori (komori.app) — https://komori.app/company/4519/disclosure/20260723598016
種別: 決算
開示日: 2026-07-23
企業ページ: https://komori.app/company/4519

## 何が変わったか

中外製薬の親会社であるロシュ・グループが、2026年1～6月の中間決算を公表した。中外製薬は公表資料の掲載先を案内し、同決算には中外製薬の同期間の業績が含まれると説明した。

## 会社が挙げた理由

記載なし

## 開示の要点

- 決算期区分: 中間期（第2四半期）
- 会計基準: not_disclosed
- 連結・個別の別: not_disclosed
- 対象期間: 2026年1月1日～6月30日
- 売上高: {"value":"not_disclosed","unit":"not_disclosed","yoy_pct":"not_disclosed"}
- 営業利益: {"value":"not_disclosed","unit":"not_disclosed","yoy_pct":"not_disclosed"}
- 経常利益: {"value":"not_disclosed","unit":"not_disclosed","yoy_pct":"not_disclosed"}
- 親会社株主に帰属する当期純利益: {"value":"not_disclosed","unit":"not_disclosed","yoy_pct":"not_disclosed"}
- １株当たり当期純利益: not_disclosed
- 売上高営業利益率: not_disclosed
- 自己資本比率: {"当期末":"not_disclosed","前期末":"not_disclosed"}
- 総資産: {"value":"not_disclosed","unit":"not_disclosed"}
- 純資産: {"value":"not_disclosed","unit":"not_disclosed"}
- 営業活動によるキャッシュ・フロー: {"value":"not_disclosed","unit":"not_disclosed"}
- 投資活動によるキャッシュ・フロー: {"value":"not_disclosed","unit":"not_disclosed"}
- 財務活動によるキャッシュ・フロー: {"value":"not_disclosed","unit":"not_disclosed"}
- 現金及び現金同等物期末残高: {"value":"not_disclosed","unit":"not_disclosed"}
- 通期業績予想: {"売上高":{"value":"not_disclosed","yoy_pct":"not_disclosed"},"営業利益":{"value":"not_disclosed","yoy_pct":"not_disclosed"},"経常利益":{"value":"not_disclosed","yoy_pct":"not_disclosed"},"純利益":{"value":"not_disclosed","yoy_pct":"not_disclosed"}}
- 業績予想の修正: {"previous_forecast":"not_disclosed","revised_forecast":"not_disclosed","change":"not_disclosed","change_rate":"not_disclosed","unit":"not_disclosed"}
- 年間配当予想: {"previous_forecast":"not_disclosed","revised_forecast":"not_disclosed","change":"not_disclosed","change_rate":"not_disclosed","unit":"not_disclosed"}
- 配当性向: not_disclosed
- 株主還元方針: not_disclosed
- セグメント別売上高: not_disclosed
- セグメント別利益: not_disclosed
- 地域別売上高: not_disclosed
- 受注高・受注残高: {"受注高":"not_disclosed","受注残高":"not_disclosed","unit":"not_disclosed"}
- 減価償却費: {"value":"not_disclosed","unit":"not_disclosed"}
- 減損損失: {"金額":"not_disclosed","対象資産":"not_disclosed"}
- 特別損益の内訳: {"特別利益":"not_disclosed","特別損失":"not_disclosed"}
- 継続企業の前提に関する記載: not_disclosed
- 会計方針の変更: {"基準改正に伴う変更":"not_disclosed","それ以外の変更":"not_disclosed","見積りの変更":"not_disclosed","修正再表示":"not_disclosed"}
- 連結範囲の変更: {"新規会社数":"not_disclosed","新規会社名":"not_disclosed","除外会社数":"not_disclosed","除外会社名":"not_disclosed"}
- 重要な後発事象: not_disclosed
- 決算補足説明資料の有無: not_disclosed
- 決算説明会の有無: not_disclosed
- 期末発行済株式数: not_disclosed
- 期末自己株式数: not_disclosed
- 業績の増減要因: not_disclosed

## 評価の根拠

- 主要な主張に検証できる数値がついているか。: 数値と時期あり（原文: 「「2026年1月1日～6月30日の業績」および「当社発行済株式の59.89％（議決権比率では61.12％）」」）